Skip to main content
Erschienen in: Japanese Journal of Ophthalmology 6/2017

28.07.2017 | Clinical Investigation

Concentration of acute phase factors in vitreous fluid in diabetic macular edema

verfasst von: Kazuhiro Kimura, Tomoko Orita, Yuka Kobayashi, Shigeo Matsuyama, Kazushi Fujimoto, Kazuhiko Yamauchi

Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Diabetic retinal maculopathy is associated with acute and chronic local inflammation. We measured the concentrations of acute phase factors in vitreous fluid of patients with diabetic macular edema (DME) and examined their relations to visual acuity and central retinal thickness (CRT) both before and after vitrectomy.

Study design

Retrospective.

Methods

Vitreous fluid was collected during vitreoretinal surgery from 19 patients with DME and 12 control subjects with epiretinal membrane. The concentrations of acute phase factors (α2-macroglobulin, haptoglobin, C-reactive protein, serum amyloid P and A, procalcitonin, ferritin, tissue plasminogen activator, fibrinogen) and vascular endothelial growth factor (VEGF) were measured with multiplex assays. CRT of macular edema was measured by optical coherence tomography (OCT).

Results

The levels of serum amyloid P, procalcitonin, ferritin, and fibrinogen in vitreous fluid were increased in DME patients compared with control subjects. The levels of procalcitonin and fibrinogen in DME patients were inversely correlated with visual acuity both before and 3 months after vitrectomy but not 6 months postsurgery. The concentrations of these four factors were not correlated with either CRT or the vitreous levels of VEGF in DME patients.

Conclusion

Acute phase factors may contribute to local inflammation in DME and may therefore influence disease progression.
Literatur
1.
Zurück zum Zitat Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122:1375–94.CrossRefPubMed Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122:1375–94.CrossRefPubMed
3.
Zurück zum Zitat Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116:73–9.CrossRefPubMed Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009;116:73–9.CrossRefPubMed
4.
Zurück zum Zitat Noma H, Mimura T, Yasuda K, Shimura M. Role of inflammation in diabetic macular edema. Ophthalmologica. 2014;232:127–35.CrossRefPubMed Noma H, Mimura T, Yasuda K, Shimura M. Role of inflammation in diabetic macular edema. Ophthalmologica. 2014;232:127–35.CrossRefPubMed
5.
Zurück zum Zitat Herpers BL, Endeman H, de Jong BA, de Jongh BM, Grutters JC, Biesma DH, et al. Acute-phase responsiveness of mannose-binding lectin in community-acquired pneumonia is highly dependent upon MBL2 genotypes. Clin Exp Immunol. 2009;156:488–94.CrossRefPubMedPubMedCentral Herpers BL, Endeman H, de Jong BA, de Jongh BM, Grutters JC, Biesma DH, et al. Acute-phase responsiveness of mannose-binding lectin in community-acquired pneumonia is highly dependent upon MBL2 genotypes. Clin Exp Immunol. 2009;156:488–94.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal. 1999;13:273–9.CrossRefPubMed Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal. 1999;13:273–9.CrossRefPubMed
7.
8.
Zurück zum Zitat Khazaei M. Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus. J Res Med Sci. 2011;16:1634–5.PubMedPubMedCentral Khazaei M. Acute phase reactant dynamics and incidence of microvascular dysfunctions in type 2 diabetes mellitus. J Res Med Sci. 2011;16:1634–5.PubMedPubMedCentral
9.
Zurück zum Zitat Camós S, Gubern C, Sobrado M, Rodríguez R, Romera VG, Moro MA, et al. The high-mobility group I-Y transcription factor is involved in cerebral ischemia and modulates the expression of angiogenic proteins. Neuroscience. 2014;269:112–30.CrossRefPubMed Camós S, Gubern C, Sobrado M, Rodríguez R, Romera VG, Moro MA, et al. The high-mobility group I-Y transcription factor is involved in cerebral ischemia and modulates the expression of angiogenic proteins. Neuroscience. 2014;269:112–30.CrossRefPubMed
10.
Zurück zum Zitat Coucha M, Elshaer SL, Eldahshan WS, Mysona BA, El-Remessy AB. Molecular mechanisms of diabetic retinopathy: potential therapeutic targets. Middle East Afr J Ophthalmol. 2015;22:135–44.CrossRefPubMedPubMedCentral Coucha M, Elshaer SL, Eldahshan WS, Mysona BA, El-Remessy AB. Molecular mechanisms of diabetic retinopathy: potential therapeutic targets. Middle East Afr J Ophthalmol. 2015;22:135–44.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens. 2001;14:475–86.CrossRefPubMed Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens. 2001;14:475–86.CrossRefPubMed
12.
Zurück zum Zitat Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, Oshima Y, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4:e8158.CrossRefPubMedPubMedCentral Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, Oshima Y, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4:e8158.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Badolato R, Oppenheim JJ. Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum. 1996;26:526–38.CrossRefPubMed Badolato R, Oppenheim JJ. Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum. 1996;26:526–38.CrossRefPubMed
14.
Zurück zum Zitat Santoro A, Mancini E. Cardiac effects of chronic inflammation in dialysis patients. Nephrol Dial Transplant. 2002;17:10–5.CrossRefPubMed Santoro A, Mancini E. Cardiac effects of chronic inflammation in dialysis patients. Nephrol Dial Transplant. 2002;17:10–5.CrossRefPubMed
15.
16.
Zurück zum Zitat Ma Y, Tao Y, Lu Q, Jiang YR. Intraocular expression of serum amyloid A and interleukin-6 in proliferative diabetic retinopathy. Am J Ophthalmol. 2011;152:678–85.CrossRefPubMed Ma Y, Tao Y, Lu Q, Jiang YR. Intraocular expression of serum amyloid A and interleukin-6 in proliferative diabetic retinopathy. Am J Ophthalmol. 2011;152:678–85.CrossRefPubMed
17.
Zurück zum Zitat Kocabora MS, Telli ME, Fazil K, Erdur SK, Ozsutcu M, Cekic O, et al. Serum and aqueous concentrations of inflammatory markers in diabetic macular edema. Ocul Immunol Inflamm. 2016;24:549–54.CrossRefPubMed Kocabora MS, Telli ME, Fazil K, Erdur SK, Ozsutcu M, Cekic O, et al. Serum and aqueous concentrations of inflammatory markers in diabetic macular edema. Ocul Immunol Inflamm. 2016;24:549–54.CrossRefPubMed
18.
Zurück zum Zitat Thornit DN, Vinten CM, Sander B, Lund-Andersen H, la Cour M. Blood-retinal barrier glycerol permeability in diabetic macular edema and healthy eyes: estimations from macular volume changes after peroral glycerol. Invest Ophthalmol Vis Sci. 2010;51:2827–34.CrossRefPubMed Thornit DN, Vinten CM, Sander B, Lund-Andersen H, la Cour M. Blood-retinal barrier glycerol permeability in diabetic macular edema and healthy eyes: estimations from macular volume changes after peroral glycerol. Invest Ophthalmol Vis Sci. 2010;51:2827–34.CrossRefPubMed
19.
Zurück zum Zitat Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1–29.CrossRefPubMed Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1–29.CrossRefPubMed
20.
Zurück zum Zitat Serizawa S, Ohkoshi K, Minowa Y, Takahashi O. Prognosis of patients with diabetic macular edema before Japanese approval of anti-vascular endothelial growth factor. Jpn J Ophthalmol. 2015;59:244–51.CrossRefPubMed Serizawa S, Ohkoshi K, Minowa Y, Takahashi O. Prognosis of patients with diabetic macular edema before Japanese approval of anti-vascular endothelial growth factor. Jpn J Ophthalmol. 2015;59:244–51.CrossRefPubMed
21.
Zurück zum Zitat Ogura Y, Shiraga F, Terasaki H, Ohji M, Ishida S, Sakamoto T, et al. Clinical practice pattern in management of diabetic macular edema in Japan: survey results of Japanese retinal specialists. Jpn J Ophthalmol. 2017;61:43–50.CrossRefPubMed Ogura Y, Shiraga F, Terasaki H, Ohji M, Ishida S, Sakamoto T, et al. Clinical practice pattern in management of diabetic macular edema in Japan: survey results of Japanese retinal specialists. Jpn J Ophthalmol. 2017;61:43–50.CrossRefPubMed
22.
Zurück zum Zitat Gardner TW, Antonetti DA. Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches. Curr Diab Rep. 2008;8:263–9.CrossRefPubMed Gardner TW, Antonetti DA. Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches. Curr Diab Rep. 2008;8:263–9.CrossRefPubMed
23.
Zurück zum Zitat Ma JX, Zhang SX, Wang JJ. Down-regulation of angiogenic inhibitors: a potential pathogenic mechanism for diabetic complications. Curr Diabetes Rev. 2005;1:183–96.CrossRefPubMed Ma JX, Zhang SX, Wang JJ. Down-regulation of angiogenic inhibitors: a potential pathogenic mechanism for diabetic complications. Curr Diabetes Rev. 2005;1:183–96.CrossRefPubMed
24.
Zurück zum Zitat Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152:686–94.CrossRefPubMed Sohn HJ, Han DH, Kim IT, Oh IK, Kim KH, Lee DY, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152:686–94.CrossRefPubMed
Metadaten
Titel
Concentration of acute phase factors in vitreous fluid in diabetic macular edema
verfasst von
Kazuhiro Kimura
Tomoko Orita
Yuka Kobayashi
Shigeo Matsuyama
Kazushi Fujimoto
Kazuhiko Yamauchi
Publikationsdatum
28.07.2017
Verlag
Springer Japan
Erschienen in
Japanese Journal of Ophthalmology / Ausgabe 6/2017
Print ISSN: 0021-5155
Elektronische ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-017-0525-x

Weitere Artikel der Ausgabe 6/2017

Japanese Journal of Ophthalmology 6/2017 Zur Ausgabe

Scientific Reviewers

Scientific Reviewers

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.